MedDataX Logo

A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers

NCT ID: NCT03164109

Last Updated: 2017-11-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-18

Study Completion Date

2017-10-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a partially double-blind study in healthy adult subjects, which will be conducted as a placebo- and active-controlled, single-dose, crossover study.

Twenty-eight subjects will be enrolled to ensure 24 subjects on all study periods. All subjects will receive all 3 study treatments (GC4419, placebo and moxifloxacin) in randomized sequence.

Cardiodynamic assessment using continuous ECG recordings (Holters) will be performed for approximately 26 hours on the day of dosing (Day 1) in each study period. ECGs will be extracted serially pre- and post-dose and predefined timepoints at which subjects will be supinely resting.

Subjects will be supinely resting for at least 10 minutes prior to and 5 minutes after each nominal timepoint for ECG extraction.

Blood draws for PK will be performed in all periods at the same timepoints and always after ECG extraction.

Subjects will be domiciled in the clinic from noon/afternoon of the day before dosing (Day -1) until completion of safety procedures on Day 2 in each study period.

All subjects (including subjects who terminate the study early) will return to the clinical research unit (CRU) 14 (± 1) days after the last administration of study treatment for follow-up procedures and to determine if any Adverse Event (AE) has occurred since the last study visit.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers Healthy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Healthy Adult Superoxide Dismutase Free Radical Dismutase Cardiodynamic Assessment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GC4419 IV

Group Type EXPERIMENTAL

GC4419 IV

Intervention Type DRUG

50mg infused IV over 15 minutes

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Infused IV over 15 minutes

Oral moxifloxacin

Group Type ACTIVE_COMPARATOR

Oral moxifloxacin

Intervention Type DRUG

400 mg tablet orally with 250 mL room temperature water

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GC4419 IV

50mg infused IV over 15 minutes

Intervention Type DRUG

Placebo

Infused IV over 15 minutes

Intervention Type DRUG

Oral moxifloxacin

400 mg tablet orally with 250 mL room temperature water

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy, adult, male or female, 18-55 years of age
2. Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dose.
3. Must weigh at least 60 kg for males or 52 kg for females and have a body mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/m2
4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or ECGs
5. For a female of childbearing potential: either be sexually inactive as a voluntary lifestyle choice for at least 1 year prior to first dosing until 21 days following last dosing or be using an acceptable birth control method
6. For a female of non-childbearing potential: must have undergone an acceptable sterilization procedure or be postmenopausal for at least 1 year prior to the first dose
7. Willing and able to comply with the protocol.
8. Seated blood pressure between 90/40 mmHg and 140/90 mmHg
9. Has serum potassium, calcium, and magnesium levels within the normal range at screening.

Exclusion Criteria

1. History or presence of clinically significant medical or psychiatric condition, disease or illness
2. History or presence of alcoholism or drug abuse within the past 2 years
3. History or presence of hypersensitivity to the study drugs
4. History of significant multiple and/or severe allergies
5. Female subjects who are pregnant or lactating.
6. Positive results at screening for human immunodeficiency virus (HIV), syphilis, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
7. Unable to refrain from or anticipates the use of any drug, including prescription and non-prescription medications 14 days prior to the first dose of study drug and throughout the study.
8. Any drugs known to be significant inhibitors or inducers of CYP enzymes and/or P-gp, including St. John's Wort, for 28 days prior to the first dose of study drug and throughout the study.
9. Has been on a diet incompatible with the on-study diet, within the 28 days prior to the first dose of study drug, and throughout the study.
10. Donation of blood or significant blood loss within 56 days
11. Plasma donation within 7 days prior to the first dose of study drug.
12. Has had surgery or any medical condition which may affect the absorption, distribution, metabolism, or elimination of the study drug within 6 months.
13. Participation in another clinical trial within 28 days
14. Participation in a previous clinical trial where subject received GC4419.
15. History or presence of: hypokalemia, risk factors for Torsades de Pointes , sick sinus syndrome, second, or third degree atrioventricular block, myocardial infarction, pulmonary congestion, cardiac arrhythmia, prolonged QT interval, or conduction abnormalities; repeated or frequent syncope or vasovagal episodes; hypertension, angina, bradycardia, or severe peripheral arterial circulatory disorders.
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Syneos Health

OTHER

Sponsor Role collaborator

Galera Therapeutics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jon T Holmlund, MD

Role: STUDY_CHAIR

Galera Therapeutics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nucleus Network Limited

Melbourne, Victoria, Australia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GTI-4419-002

Identifier Type: -

Identifier Source: org_study_id